Abstract
Purpose of ReviewTo examine the role of endosomal dysfunction in heart failure pathophysiology and evaluate its potential as a therapeutic target, particularly focusing on its regulation of cardiac metabolism.Recent FindingsEndosomal dysfunction, driven by v-ATPase disassembly and loss of acidification, emerges as a key contributor to metabolic perturbations in heart failure. This dysfunction leads to uncontrolled CD36 translocation, resulting in lipotoxicity and inflammatory signaling through CD36-TLR4 complex formation. These mechanisms are especially relevant in diabetic cardiomyopathy and heart failure with preserved ejection fraction.SummaryThe endosomal system represents a promising therapeutic target in heart failure, though its contribution varies among patients and disease stages. Recent advances in molecular imaging and biomarker analysis enable better patient stratification, opening new avenues for personalized endosome-targeted therapies in heart failure treatment.
| Original language | English |
|---|---|
| Article number | 38 |
| Number of pages | 15 |
| Journal | Current Heart Failure Reports |
| Volume | 22 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Dec 2025 |
Keywords
- Endosomal function
- v-ATPase
- Cardiac metabolism
- CD36
- REDUCED EJECTION FRACTION
- VACUOLAR H+-ATPASE
- MYOCARDIAL FATTY-ACID
- V-ATPASE
- INSULIN-RESISTANCE
- LIPID-ACCUMULATION
- METABOLISM
- DYSFUNCTION
- INHIBITION